165 related articles for article (PubMed ID: 16386661)
1. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial.
Singh M; Williams BA; Gersh BJ; McClelland RL; Ho KK; Willerson JT; Penny WF; Cutlip DE; Holmes DR
J Am Coll Cardiol; 2006 Jan; 47(1):34-9. PubMed ID: 16386661
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
Singh M; Gersh BJ; McClelland RL; Ho KK; Willerson JT; Penny WF; Holmes DR
J Am Coll Cardiol; 2005 Jan; 45(2):198-203. PubMed ID: 15653015
[TBL] [Abstract][Full Text] [Related]
3. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.
Garot P; Lefèvre T; Savage M; Louvard Y; Bamlet WR; Willerson JT; Morice MC; Holmes DR
J Am Coll Cardiol; 2005 Aug; 46(4):606-12. PubMed ID: 16098423
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
Mathew V; Gersh BJ; Williams BA; Laskey WK; Willerson JT; Tilbury RT; Davis BR; Holmes DR
Circulation; 2004 Feb; 109(4):476-80. PubMed ID: 14732749
[TBL] [Abstract][Full Text] [Related]
5. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
Holmes DR; Savage M; LaBlanche JM; Grip L; Serruys PW; Fitzgerald P; Fischman D; Goldberg S; Brinker JA; Zeiher AM; Shapiro LM; Willerson J; Davis BR; Ferguson JJ; Popma J; King SB; Lincoff AM; Tcheng JE; Chan R; Granett JR; Poland M
Circulation; 2002 Sep; 106(10):1243-50. PubMed ID: 12208800
[TBL] [Abstract][Full Text] [Related]
6. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial.
Singh M; Gersh BJ; McClelland RL; Ho KK; Willerson JT; Penny WF; Holmes DR
Circulation; 2004 Jun; 109(22):2727-31. PubMed ID: 15173022
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial.
Bestehorn HP; Neumann FJ; Büttner HJ; Betz P; Stürzenhofecker P; von Hodenberg E; Verdun A; Levai L; Monassier JP; Roskamm H
J Am Coll Cardiol; 2004 Jun; 43(12):2160-5. PubMed ID: 15193674
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
[TBL] [Abstract][Full Text] [Related]
9. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.
Best PJ; Berger PB; Davis BR; Grines CL; Sadeghi HM; Williams BA; Willerson JT; Granett JR; Holmes DR;
J Am Coll Cardiol; 2004 Nov; 44(9):1786-91. PubMed ID: 15519008
[TBL] [Abstract][Full Text] [Related]
10. The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2).
Tamai H; Katoh K; Yamaguchi T; Hayakawa H; Kanmatsuse K; Haze K; Aizawa T; Nakanishi S; Suzuki S; Suzuki T; Takase S; Nishikawa H; Katoh O
Am Heart J; 2002 Mar; 143(3):506-13. PubMed ID: 11868058
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
[TBL] [Abstract][Full Text] [Related]
12. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
Pinto DS; Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Mehran R; Na Y; Turco M; Caputo R; Popma JJ; Cutlip DE; Russell ME; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(1):32-6. PubMed ID: 16814645
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with prior percutaneous revascularization undergoing repeat coronary intervention (from the PRESTO Trial).
Arjomand H; Willerson JT; Holmes DR; Bamlet WR; Surabhi SK; Roukoz B; Espinoza A; McClelland RL; McCormick DJ; Goldberg S;
Am J Cardiol; 2005 Sep; 96(6):741-6. PubMed ID: 16169350
[TBL] [Abstract][Full Text] [Related]
14. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial.
Holmes D; Fitzgerald P; Goldberg S; LaBlanche Jm; Lincoff AM; Savage M; Serruys PW; Willerson J; Granett JR; Chan R; Shusterman NH; Poland M
Am Heart J; 2000 Jan; 139(1 Pt 1):23-31. PubMed ID: 10618558
[TBL] [Abstract][Full Text] [Related]
15. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease?
Klein LW
J Am Coll Cardiol; 2006 Jan; 47(1):22-6. PubMed ID: 16386659
[TBL] [Abstract][Full Text] [Related]
16. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
[TBL] [Abstract][Full Text] [Related]
18. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A
Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230
[TBL] [Abstract][Full Text] [Related]
19. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial).
Assali AR; Moustapha A; Sdringola S; Denktas AE; Willerson JT; Holmes DR; Smalling RW
Am J Cardiol; 2006 Sep; 98(6):729-33. PubMed ID: 16950172
[TBL] [Abstract][Full Text] [Related]
20. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
Yeh RW; Normand SL; Wolf RE; Jones PG; Ho KK; Cohen DJ; Cutlip DE; Mauri L; Kugelmass AD; Amin AP; Spertus JA
Circulation; 2011 Oct; 124(14):1557-64. PubMed ID: 21900079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
